Q3 2026 Medpace Holdings, Inc. Earnings Conference Call - MEDPACE HOLDINGS INC

Financial Performance:

• Q3 2026 revenue reached $716 million (up 8.5% YoY); YTD revenue (9 months) was $2.13 billion (up 16.9% YoY).
• Full-year 2026 revenue guidance raised to $2.835–$2.855 billion (12%–12.8% growth).
• Q3 EBITDA was $172.1 million (up 16% YoY) with a 24% margin; YTD EBITDA was $474.9 million (up 19.5% YoY) at a 22.3% margin.
• Full-year 2026 EBITDA guidance set at $638–$652 million (14.4%–16.9% growth).
• Q3 net income was $137.5 million (up 23.7% YoY); YTD net income was $382.7 million (up 21.1% YoY).
• Full-year 2026 net income guidance is $514–$524 million ($17.97–$18.32 per diluted share).
• Net new business awards in Q3 totaled $873.4 million (up 10.6% YoY); trailing 12-month awards grew 23.9% to $3.02 billion.
• Ending backlog as of September 30, 2026, was approximately $3.2 billion (up 5.6% YoY), with $1.99 billion expected to convert to revenue in the next 12 months.
• Cash flow from operating activities was $216.6 million; net days sales outstanding (DSO) was negative 66 days; cash balance stood at $705.3 million.
• Top five and ten customers represented 31% and 39% of the last 12 months' revenue, respectively.
• Board terminated previous share repurchase authorization and approved a new $1 billion authorization effective October 20, 2026.

Guidance and Future Outlook:

• Management deferred 2027 guidance until the Q4 2026 earnings release in February due to evolving cancellation trends and Q4 award finality.
• Current modeling suggests no significant disconnect from analyst consensus for 2027, which is expected to show lower growth rates than historical norms.
• Revenue growth expectations for 2027 are anticipated to improve as cancellation rates stabilize.
• A new expansion in Cincinnati is expected to add approximately $20 million in operating costs in 2027.
• 2026 guidance assumes a full-year effective tax rate of 19%–19.5% and interest income of $22.9 million.
• Management expects Q4 to be a record-setting quarter for awards, barring unexpected cancellations.

Business Segments and Product Lines:

• Therapeutic mix is shifting toward traditional oncology, with reduced demand in the metabolic sector currently, though pending metabolic opportunities remain robust.
• Direct fee revenue margins remain strong, though management notes quarter-to-quarter volatility due to ASC 606 revenue recognition timing.
• Management highlighted the success of process adjustments made in late 2025 to improve win rates.
• The business continues to prioritize full-service engagement, though it remains open to front-end only projects if they offer significant value, while excluding pure functional service model (FSP) carve-outs.
• Large pharma growth is largely organic from acquired biotech clients rather than new direct outreach.

Market and Competitive Landscape:

• The business environment is described as "strong" with high-quality RFP activity and a "good win rate."
• Win rate improvements are attributed to strategic process changes implemented in late 2025.
• Competitive dynamics have normalized, moving away from the aggressive pricing strategies seen in previous years.
• Customer decision timelines are faster than the prior year, with fewer RFPs being bid by a wide array of competitors.
• Pass-through revenue mix is expected to remain around 40%–40.5% for the remainder of the year.
• Cancellations have shifted from being primarily funding-driven to being driven by product failure, safety signals, and prioritization.

Risks and Challenges:

• Cancellations remain a primary risk, with Q3 cancellations noted as "toward the higher end" of expectations, driven by unexpected product failures.
• Future growth rates in 2027 are constrained by the normalization of cancellation patterns compared to previous years.
• Margin sustainability is subject to quarterly volatility related to contract timing and revenue recognition (ASC 606).
• The Cincinnati campus expansion presents a near-term cost headwind in 2027.
• Market risk regarding potential increases in turnover rates and salary inflation is currently assessed as low, with no abnormal pressure reported.

Management Commentary and Tone:

• Tone was confident yet cautious regarding 2027, emphasizing the need to observe Q4 cancellation and award data before providing specific future guidance.
• CEO August Trundle emphasized that "book-to-bill" is a poor metric, preferring to focus on award growth and trailing 12-month trends.
• Management expressed optimism about the pipeline volume and award momentum, stating Q4 could be another record for new awards.
• CFO Kevin Brady and CEO Trundle reiterated that current consensus estimates are reasonable and in line with internal modeling.

Analyst Questions and Answers:

• Win Rates & Competition: Analysts asked about competitive pressures; Management confirmed strong win rates due to improved internal processes and a shift in therapeutic mix toward oncology.
• Cancellation Drivers: Management clarified that cancellations are now primarily due to product failure and safety signals rather than funding availability.
• 2027 Guidance: Management explained the delay in 2027 guidance to allow for more accurate modeling of Q4 awards and cancellation patterns before February.
• Margin Composition: Analysts inquired about margin drivers; Management attributed strong Q3 margins to favorable mix and lower reimbursable costs, while warning of Q4 volatility.
• Work Mix: Discussions revealed no significant shift toward FSP or biometrics carve-outs, with MedPace maintaining a preference for full-service trials.
• Human Capital: Management reported low turnover rates and no abnormal pressure on salaries or benefits, contrasting with industry chatter about rising attrition.

Other Key Points:

• The company views the volume of pending RFP decisions and total dollar value of opportunities as high, despite a slight dip in raw RFP counts.
• Backlog inflation is driven by the entry of new projects with longer durations and the timing of short-duration project completions rather than a specific shift in therapeutic type.
• Pass-through expenses are noted as a directional proxy for direct fee revenue but are not a precise financial metric.
• The earnings call included a standard forward-looking statement disclaimer regarding risks and uncertainties outlined in SEC filings.